Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah-Reference-Cited by-同舟云学术

Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah

Published:2020-10-08 Issue: Volume: Page:1-11
ISSN:1744-1692
Container-title:Global Public Health
language:en
Short-container-title:Global Public Health

Author:

Abbas Muhammad Zaheer¹^ORCID

Affiliation:

1. Faculty of Law, Queensland University of Technology (QUT), Brisbane, Australia

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/17441692.2020.1825769

Reference42 articles.

1. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma

2. FDA Approval of Tisagenlecleucel

3. Charles, N. (2019a). Oppositions to the grant of European Parent No. 3214091/17153799.6 in the name of: The Trustees of the University of Pennsylvania.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review);International Journal of Oncology;2024-02-22

2. India’s Distinct but Opposing Patent Model Is Under Pressure: Prospects and Challenges in the Global Arena;India Quarterly: A Journal of International Affairs;2024-02-04

3. Cognitive Foundations of Society: The Concept of Schemata in Cell, Gene, and Tissue Therapies;Applied Linguistics;2023-12-20

4. Strategic Use of Patent Opposition Safeguard to Improve Equitable Access to Innovative Health Technologies: A Case Study of CAR T-Cell Therapy Kymriah;SSRN Electronic Journal;2023

5. COVID-19 and the Issue of Affordable Access to Innovative Health Technologies: An Analysis of Compulsory Licensing of Patents as a Policy Option;Law and Economics of the Coronavirus Crisis;2022